convertases. It performs this function in an intrinsic fashion, being expressed at high copy number on the surface of most serum-exposed cells, so preventing amplification of complement on these cells. The interactions between CD55 and the convertases have been much studied and are described elsewhere [l-61; however, CD55 also participates in many non-complement (non-C) interactions. I t has been known for some time that, as for many other regulators of complement, a range of viral and bacterial pathogens have evolved to take advantage of cell surface CD55 to promote cellular adhesion (and often invasion) and, recently, another non-C interaction has been defined for CD55 with the identification of a new host ligand, CD97. CD97 is a molecule whose expression on the surface of leucocytes is massively up-regulated following leucocyte activation and, although the physiological consequences of a CD55-CD97 interaction are still to be defined, the characteristics of the protein-protein interaction have been much studied. A description and comparison of these non-C interactions, both pathogenic and natural, will form the basis of this review.
Structure of CD55
CD55 is an extracellular glycoprotein with a relative molecular mass of approximately 70000 attached to the cell membrane by a glycosylphosphatidyl inositol anchor belongs to the RCA (regulator of complement activation) family, a group of closely-linked genes on chromosome 1 which are built almost entirely from a small protein module termed a short consensus repeat (SCR, also known as complement control protein modules) [9] . SCRs are small (approx. 60 residues) modules containing four completely conserved cysteine residues and a generally conserved tryptophan residue, which NMR and X-ray crystallographic structures [1&14] have shown are essential for maintenance of the 8-barrel architecture of the module. The pstrands are linked together at the top and bottom of the module via two intra-module disulphide bonds. Other than these key residues, few positions show significant levels of conservation and reflect the adaptability of this module to a wide range of functions, the module architecture being compatible with many different amino acid sequences. T o date the protein data bank contains structures for 14 different SCR domains from five proteins and, taken as a whole, these now allow reasonably accurate modelling of those SCRs (such as those from CD55) for which no structure is known.
As for most other RCA family members, CD55 contains multiple copies of the SCR module (four in total) with specific biological functions generally mapping to multiple SCR domains [2, 4, . For this reason, knowledge of the orientation of the SCRs with respect to each other is crucial for the understanding of the precise structural basis for the biological functioning of CD55. Although some progress has been made towards a three-dimensional structure [19, 20] of CD55, we do not at present have an atomic structure for any part of this molecule. Two models of the four SCRs have been published [1, 5] ; however, as analysis of other structures of SCR-containing proteins has shown severe limitations in the ability to predict SCR-SCR orientations, actual atomic structures of CD55 (and probably those of CD55 in functional complexes with its ligands) are essential for a full structure-based understanding of the biology of this protein.
CD55 as a viral receptor
It is nearly a decade since the first identification of CD55 as a receptor for severai echoviruses [21, 22] and, since that time, many enteroviruses have also been shown to bind CD55 [15,21-281. Enteroviruses are members of the Picornaviridae: small, spherical, non-enveloped, positive strand RNA viruses. T h e viruses shown to bind CD55 are associated with a variety of clinical conditions that range from diarrhoea and rashes to viral meningitis and carditis. In young children, severe respiratory disease may result, with occasional fatal disease in neonates.
Our understanding of Picornavirus-receptor interactions is built upon a strong structural foundation of atomic structures of intact virions [29-381 and their receptors in isolation [13,39-411, and low resolution (20-25 A) cryo-electron microscopy-derived structures of complexes between a few viruses and their cognate receptors [42-471. Adding to this are studies of the kinetics of the virus-receptor interactions [47-501 and mutational studies of both the receptors and viruses [13, 24, 37, 51, 521 . These studies led to a general model of an enterovirus-receptor interaction as consisting of penetration of the tip of a receptor into a depression (termed 'the canyon' [53]) on the virus surface, which protects the conserved receptor- Our study of the affinity and kinetics of the binding of echovirus 11 to CD55 also showed this to be an unusual picornavirus-receptor interaction in that it was a low affinity binding event (with a K,, of approx. 3 p M ) characterized by rapid onand off-rates. However, the apparent affinity of the whole virus binding to a cell is likely to be much higher due to the potential for multivalent attachment (the virus has 60 potential binding sites for CD55). These results, taken in combination, suggested that the binding site on the virus was likely to be much more exposed than the classical [37, 55] , although the precise location on the virion varies from virus to virus. This is perhaps not so surprising, given that the CD55 domain recognized also varies, leaving no reason to expect the same site on the virus to be used. Direct confirmation of the mode of CD55-virus binding has recently been provided by a lowresolution structure of CD55 in complex with echovirus 7 [46] . Although the limited resolution provided by cryo-electron microscopy means that it is not possible to use this structure to provide detailed information about the complex, CD55 is clearly seen to bind away from the canyon at the 2-fold axes of the virion. This exposed binding site fits with the predictions which were based on mutagenesis and affinity studies. Further understanding awaits structures of other virion-CD55 complexes and higher resolution analyses.
CD55 as a bacterial receptor
Bacterial adhesins are important virulence factors that allow colonization of the human urogenital tract by Escherichia coli. T (Table 1) . T o date, we have no further information about the structures of these molecules or a more detailed characterization of the interaction, but recent work has begun to demonstrate a role for pathogen-CD5 5 interactions that goes beyond simply providing a convenient hook for the invading pathogen to bite. T h e elegant vork of Tieng et al. [62] shows that binding oi E. coli expressing AfaE to CD55 in the intestinal epithelium rapidly induces expression of the distant major histocompatibility complex (MHC) class I homologue, MICA (MHC class I chainrelated A). MICA interacts with NKG2D, a lectin-like receptor widely distributed on natural killer cells, to activate a signalling pathway, resulting in increased production of interferon-y, showing a direct link between bacterial adherence and the inflammatory state within the gut. The authors propose that, in susceptible people, this host-bacteria interaction could play a role in triggering inflammatory bowel disease.
CD55 as a ligand for CD97
T h e final CD55 non-C interaction that I will discuss here is that with the molecule CD97. CD97 is a member of the E G F (epidermal growth factor)-TM7 family, a group of cell-surface molecules characterized by a unique chimaeric structure in which tandem E G F repeats are coupled to a G-protein-coupled receptor moiety via a mucinlike stalk [63, 64] . CD97 exists in a variety of splice forms, each of which binds CD55 with different affinity [65, 66] . T h e CD55-binding splice variant with the highest affinity comprises three E G F domains (domains 1, 2 and 5 ) , two of which (domains 2 and 5 ) are predicted to be calciumbinding domains. EGFs are similar to SCR domains in that they are small, all P-domains, strengthened by disulphide bonds (three in the case of EGFs, rather than the two found in SCRs). CD97 is expressed on monocytes and granulocytes and is rapidly up-regulated on the activation of T and B cells. Although the precise biological role of the CD55-CD97 interaction is not yet clear the leucocyte-restricted expression pattern of CD97 and the presence of both molecuies in arthritic joints suggests possible roles in mediating adhesion and signalling within the inflammatory and immune responses.
T h e identification of CD97 as a ligand for CD55 seemed to fill a gap for CD55 as, when mapping of the interaction onto CD55 was performed using domain deletionlswapping approaches, it revealed a host-related function for SCRl of CD55 [16] . Thus, with the characterization of this interaction, natural functions can be ascribed to all of the extracellular SCR domains of CD55. As for the virus-CD55 interaction, the CD55-CD97 interaction was found to be of low affinity ( K , of approx. 9 0 p M [67] ). Further analysis of other CD55-ligand interactions is required to see if this will prove to be a general feature of CD55-related binding events.
The future
Our general picture of non-C CD55 interactions is filling out and we can begin to look for similarities and differences between the various classes of events; however, there are still many gaping holes in our knowledge. Firstly, both the lack of structural information in general and, specifically, the lack of structural information about complexes, mean that our understanding is necessarily rather limited at present. Secondly, the lack of information about the biological consequences of these interactions raises many questions, as follows. Do pathogen-CD55 interactions generally lead to signalling events that the pathogen can exploit or that enable the host to begin an early defence? What is the biological relevance of CD55-CD97 adhesion ? Should we worry about transplantation programmes that introduce human CD55 into other species perhaps providing a route by which novel pathogens can jump the species barrier ? All these and many other questions remain to be answered.
Many discussions over the years have contributed to the ideas presented in this review. I would particularly like to acknowledge the intellectual and practical contributions made by Dr 0. Evans (Univenity of Glasgow), Dr). Billington (Untversty of Oxford) for reading the rnanuscnpt at short notice, and the long-term funding provided by the Wellcome Trust and Arthritis Research Campaign. mation and tissue destruction is an important drive to pathology in diseases as diverse as rheumatoid arthritis and dementia. Two decades ago there were no agents that could be used therapeutically to inhibit the activation of complement, but increased understanding of the natural control of complement in vim has markedly changed this situation. T h e realization that drugs mimicking the action of the complement regulatory proteins present on self cells, and in plasma, could effectively control pathological activation of complement has opened the door to the use of anticomplement therapy in disease. Here we will review the development of anticomplement therapeutics from the first generation agents, which are unmodified recombinant forms of natural regulators, to recent strategies for making better drugs. We will describe strategies for targeting the anticomplement activity to the site of disease, and for extending the plasma half-life of the agent. Finally, we will illustrate a novel approach to the
